COMP <GO>
CTMX vs JNJ // GROSS PROFIT MARGIN
CytomX Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CTMX 0
— JNJ 9
■ METRIC PARITY
LAST: $2.29 (-2.97%) • MKT CAP: $499.0M
gross-margins
—
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTMX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTMX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | 25.50% | -46.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.19% | 2.97% | -18.16 | JNJ | /fcf-yield <GO> |
| Operating Margin | -29.30% | 34.70% | -64.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -22.80% | 28.50% | -51.30 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -44.80% | 6.00% | -50.80 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.59 | -5.39 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 8/9 | -7.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.7 | 62.1 | -19.40 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $499.0M | $662.49B | -$661.99B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTMX REV | JNJ REV | CTMX GROSS % | JNJ GROSS % | CTMX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $76.2M | $94.19B | — | 67.9% | -$75.8M | $19.70B |
| FY 2024 | $138.1M | $88.82B | — | 69.1% | -$86.5M | $19.84B |
| FY 2023 | $101.2M | $85.16B | — | — | -$56.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTMX // BETA —
JNJ // BETA 1.08